Warm Autoimmune Hemolytic Anemia Treatment Guidelines

Introduction to Treatment

• The American College of Physicians recommends administering high-dose intravenous methylprednisolone at ≥1 mg/kg daily as early as possible for warm autoimmune hemolytic anemia requiring IV steroids, particularly in severe or acute presentations 1

Treatment Stratification by Severity

• For patients with hemoglobin <10.0 to 8.0 g/dL, the American Society of Hematology suggests initiating oral prednisone 0.5-1 mg/kg/day, which represents the threshold where corticosteroid therapy becomes necessary 1, 2
• For symptomatic patients with hemoglobin <8.0 g/dL or transfusion indicated, the European Hematology Association recommends administering prednisone 1-2 mg/kg/day, with IV route preferred 1

First-Line IV Steroid Regimen

• The standard approach is high-dose IV methylprednisolone at doses ≥1 mg/kg daily, with treatment response monitored through hemoglobin levels, reticulocyte count, and DAT 1

Important Caveats

• The American Society of Hematology advises avoiding IV anti-D in patients with autoimmune hemolytic anemia, as it can exacerbate hemolysis 1, 2, 3

Second-Line Options for Steroid-Refractory Disease

• For patients who fail to respond adequately to IV steroids, the National Comprehensive Cancer Network recommends rituximab (375 mg/m² weekly for 4 weeks) as the preferred second-line treatment with 70-80% effectiveness 1